Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
OncoTherapy ScienceTSE:4564 46 Cash Ratio is 12.29 as of Mar. 2026, which is 4% below its 10-year median of 12.75. GuruFocus rates TSE:4564 with a GF Score™ of 46/100 and a GF Value™ of 円18.05 (Modestly Overvalued). The stock has 1 warning sign investors should review. Among 1,383 Biotechnology companies, OncoTherapy Science ranks better than 82.28% on this metric.
OncoTherapy Science has a Cash Ratio of 12.29. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for OncoTherapy Science's Cash Ratio or its related term are showing as below:
TSE:4564'
s Cash Ratio Range Over the Past 10 Years
Min: 1.47 Med: 12.75 Max: 27.23
Current: 10.72
During the past 13 years, OncoTherapy Science's highest Cash Ratio was 27.23. The lowest was 1.47. And the median was 12.75.
TSE:4564's Cash Ratio is ranked better than 82.28% of 1383
companies
in the Biotechnology industry
Industry Median: 2.94
vs TSE:4564: 10.72
OncoTherapy Science (TSE:4564) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
OncoTherapy Science Cash Ratio Related Terms
OncoTherapy Science Cash Ratio Historical Data
* Premium members only.
The historical data trend for OncoTherapy Science's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4564 vs VRTX, REGN, MRNA: Cash Ratio Comparison
For the Biotechnology subindustry, OncoTherapy Science's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
OncoTherapy Science Cash Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, OncoTherapy Science's Cash Ratio distribution charts can be found below:
* The bar in red indicates where OncoTherapy Science's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OncoTherapy Science (TSE:4564) has a Cash Ratio of 12.29 as of Mar. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on OncoTherapy Science and its competitors. This is near median its historical median of 12.75. Over the past decade, OncoTherapy Science's Cash Ratio has ranged from 1.47 to 27.23. According to the industry distribution chart, OncoTherapy Science ranks #245 out of 1383 companies in the Biotechnology industry, placing it in the top 17.7%.
Is OncoTherapy Science's Cash Ratio too high?
OncoTherapy Science's current Cash Ratio of 12.29 is near median its 10-year median of 12.75. Over the past 10 years, this metric has ranged from a low of 1.47 to a high of 27.23. The Biotechnology industry median Cash Ratio is 2.94. OncoTherapy Science's value of 12.29 is 318% above this industry median. Based on the distribution chart, OncoTherapy Science ranks #245 out of 1383 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, OncoTherapy Science has a GF Score™ of 46/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does OncoTherapy Science's Cash Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, OncoTherapy Science ranks #245 out of 1383 companies for Cash Ratio. This places OncoTherapy Science in the top 18% of its industry — outperforming the majority of peers. The industry median Cash Ratio is 2.94. OncoTherapy Science's value of 12.29 is 318% above this benchmark. Historically, OncoTherapy Science's own Cash Ratio has ranged from 1.47 to 27.23 over the past decade. While the company's 10-year median is 12.75 vs. the industry median of 2.94, OncoTherapy Science has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Biotechnology company?
The median Cash Ratio among Biotechnology companies is 2.94, based on 1,383 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. OncoTherapy Science's current Cash Ratio of 12.29 is 318% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on OncoTherapy Science and its competitors. For the Biotechnology industry, the median Cash Ratio is 2.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. OncoTherapy Science's current Cash Ratio is 12.29, which is near median its own 10-year median of 12.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OncoTherapy Science stock overvalued right now?
Based on GuruFocus' analysis, OncoTherapy Science (TSE:4564) is currently considered Modestly Overvalued. The stock's GF Value™ is 円18.05, compared to a current price of 円22.00 — trading 21.9% above its estimated fair value. The current Cash Ratio is 12.29, which is near median its 10-year median of 12.75 and 318% above the Biotechnology industry median of 2.94. OncoTherapy Science's overall GF Score™ is 46/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For OncoTherapy Science (TSE:4564), the current Cash Ratio is 12.29 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is OncoTherapy Science (TSE:4564) Overvalued in 2026?
Based on GuruFocus' analysis, OncoTherapy Science stock appears to be overvalued.
The current stock price of 円22.00 is trading 21.9% above its estimated GF Value™ of 円18.05.
GuruFocus considers OncoTherapy Science to be Modestly Overvalued.
Key valuation signals for TSE:4564:
Cash Ratio: 12.29 (near median its 10-year median of 12.75)
GF Value™: 円18.05 vs. price of 円22.00 (21.9% above fair value)
Industry Position: 318% above the Biotechnology median (#245 of 1383)
No single metric tells the full story. See the TSE:4564 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
OncoTherapy Science Inc focuses on cancer-related cells and genes and develops cancer therapy products which include low molecular drugs, antibody drugs, cancer peptide vaccine, and diagnostic medicine in Japan.
46GF Score
Get the complete analysis for TSE:4564
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4564 has been successfully added to your 
